Guardant Health, Inc. (BIT:1GH)
Italy · Delayed Price · Currency is EUR | Market Cap | 20.16B +86.4% |
| Revenue (ttm) | 1.04B +42.7% |
| Net Income | -396.89M |
| EPS | -3.12 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 157.76 |
| Previous Close | 159.04 |
| Day's Range | 157.76 - 157.76 |
| 52-Week Range | 52.76 - 159.04 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Guardant Health
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transc... [Read more]
Financial Performance
In 2025, Guardant Health's revenue was $982.02 million, an increase of 32.88% compared to the previous year's $739.02 million. Losses were -$416.28 million, -4.61% less than in 2024.
Financial numbers in USD Financial StatementsNews
Guardant Health price target raised to $220 from $210 at TD Cowen
TD Cowen raised the firm’s price target on Guardant Health (GH) to $220 from $210 and keeps a Buy rating on the shares. The frm updated its model following strong…
Guardant Health price target lowered to $196 from $220 at Baird
Baird lowered the firm’s price target on Guardant Health (GH) to $196 from $220 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results.
Guardant Health reports Q3 adjusted EPS (29c), consensus (31c)
Reports Q3 revenue $361M, consensus $350.64M. “Revenue grew 36% year over year as we continued to execute across Oncology, Screening, and Biopharma,” said Helmy Eltoukhy, co-founder and co-CEO. “Oncol...
Guardant Health raises FY26 revenue $1.36B-$1.37B from $1.34B-$1.36B
Consensus $1.36B. Guardant Health (GH) now expects full year 2026 non-GAAP gross margin to be 65%, compared to prior guidance of 64% to 65%. The company expects total non-GAAP operating…
Guardant Health Earnings Call Transcript: Q3 2026
Q3 revenue grew 36% to $361M, led by oncology and rapid Shield adoption, and FY26 revenue guidance rose to $1.36B–$1.37B. Adjusted EBITDA loss narrowed to $37M; free cash flow breakeven remains targeted by end-2027.
Guardant Health Earnings release: Q3 2026
Guardant Health released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Guardant Health Slides: Q3 2026
Guardant Health has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Guardant Health Quarterly report: Q3 2026
Guardant Health has published its Q3 2026 quarterly earnings report on November 5, 2026.
Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2026. Third Q...
Kevin Sayer Joins Guardant Health Board of Directors
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Kevin Sayer to its board of directors. Mr. Sayer is for...
Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced it received the 2026 Prix Galien USA Award for Best Medical Technology for Shiel...
Guardant Health ‘applauded’ new law in PA for colorectal cancer screening
Guardant Health (GH) “applauded” the enactment of a new law in Pennsylvania, PA, aligning insurance coverage for colorectal cancer screening to reflect the latest American Cancer Society, ACS, and Nat...
Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, applauded the enactment of a new law (HB 1123) in Pennsylvania aligning insurance coverage...
Guardant Health price target raised to $210 from $195 at BTIG
BTIG analyst Mark Massaro raised the firm’s price target on Guardant Health (GH) to $210 from $195 and keeps a Buy rating on the shares as part of a broader…
Roth starts Guardant Health with Buy on ‘premium growth’
Roth Capital analyst Max Masucci initiated coverage of Guardant Health (GH) with a Buy rating and $200 price target The firm believes the company can post “premium growth” through its…
Guardant Health initiated with a Buy at Roth Capital
Roth Capital initiated coverage of Guardant Health (GH) with a Buy rating and $200 price target
Guardant to present 25 abstracts on liquid biopsy research portfolio at ESMO
Guardant Health (GH) announced that the company and its research collaborators will present 25 abstracts-including five rapid oral presentations-demonstrating advances in methylation-based circulating...
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—...
TwinStrand Biosciences says US PTABL rejects Guardant challenge to patent
TwinStrand Biosciences “announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has again rejected Guardant Health, Inc.’s (GH) challenge to a core patent underlying...
Guardant presents data from role of blood-based testing in CRC screening
Guardant Health (GH) announced the company and its research collaborators presented new data showing the critical role of blood-based testing in increasing overall colorectal cancer, CRC, screening an...
Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing the ...
Guardant Health price target raised to $200 from $185 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh raised the firm’s price target on Guardant Health (GH) to $200 from $185 and keeps an Overweight rating on the shares as the firm refreshed…
Guardant Health price target raised to $200 from $195 at BofA
BofA raised the firm’s price target on Guardant Health (GH) to $200 from $195 and keeps a Buy rating on the shares as part of a specialty diagnostics group preview…
Guardant announces Europe approval of Guardnat360 CDx as Etcamaha companion
Guardant Health (GH) announced that Guardant360 CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic to identify patients with estrogen r...
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360® CDx has received CE-marking under Europe's in Vitro Diag...